[go: up one dir, main page]
Jump to content

Mosapramine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m Quick-adding category Dibenzazepines (using HotCat)
change generic short description
 
(46 intermediate revisions by 28 users not shown)
Line 1: Line 1:
{{Short description|Antipsychotic medication}}
{{Drugbox
{{Drugbox
| verifiedrevid = 444061994
| IUPAC_name = 1'-[3-(3-chloro-10,11-dihydro-5''H''-dibenzo[''b,f'']azepin-5-yl)propyl]hexahydro-2''H''-spiro[imidazo[1,2-''a'']pyridine-3,4'-piperidin]-2-one
| IUPAC_name = 1'-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]spiro[1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-3,4'-piperidine]-2-one
| image = Mosapramine.png
| image = Mosapramine.svg
⚫
| CAS_number = 89419-40-9
| width = 250
⚫
| ATC_prefix = N05
| image2 = Mosapramine-xtal-1993-ball-and-stick.png
⚫
| ATC_suffix = AX10
| width2 = 250
⚫
| PubChem = 4257

<!--Clinical data-->
| tradename = Cremin (クレミン, <small>[[Japan|JP]]</small>)
| Drugs.com = {{drugs.com|international|mosapramine}}
⚫
| pregnancy_category =
⚫
| legal_status = Rx-only (<small>[[Japan|JP]]</small>)
⚫
| routes_of_administration = [[Mouth|Oral]] (tablets, oral solution)

<!--Pharmacokinetic data-->
⚫
| bioavailability =
⚫
| metabolism =
⚫
| elimination_half-life =
⚫
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
⚫
| CAS_number = 89419-40-9
⚫
| ATC_prefix = N05
⚫
| ATC_suffix = AX10
⚫
| PubChem = 4257
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 04UZQ7O9SJ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08235
| ChemSpiderID = 4107
| DrugBank = DB13676

<!--Chemical data-->
| C=28 | H=35 | Cl=1 | N=4 | O=1
| C=28 | H=35 | Cl=1 | N=4 | O=1
⚫
| smiles = C1CCN2C(C1)NC(=O)C23CCN(CC3)CCCN4C5=CC=CC=C5CCC6=C4C=C(C=C6)Cl
| molecular_weight = 479.057 g/mol
| StdInChI = 1S/C28H35ClN4O/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34)
⚫
| smiles = C1CCN2C(C1)NC(=O)C23CCN(CC3)CCCN4C5=CC=CC=C5CCC6=C4C=C(C=C6)Cl
| StdInChIKey = PXUIZULXJVRBPC-UHFFFAOYSA-N
⚫
| bioavailability =
| protein_bound =
⚫
| metabolism =
⚫
| elimination_half-life =
⚫
| excretion =
⚫
| pregnancy_category=
⚫
| legal_status = Rx-only
⚫
| routes_of_administration = Oral
}}
}}


'''Mosapramine''' is an [[atypical antipsychotic]].<ref>Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. ''Neuropsychobiology''. 1999;39(2):81-5. PMID 10072664</ref> It is a potent [[dopamine antagonist]] with high affinity to the [[Dopamine receptor D2|D<sub>2</sub>]], [[Dopamine receptor D3|D<sub>3</sub>]], and [[Dopamine receptor D4|D<sub>4</sub>]] [[Receptor (biochemistry)|receptors]],<ref>Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T. The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors. ''Nippon Yakurigaku Zasshi''. (Japanese) 1996 May;107(5):247-53. PMID 8690306</ref> and with moderate affinity for the [[5-HT2 receptor|5-HT<sub>2</sub> receptors]].<ref>Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. ''Neuropsychopharmacology''. 1995 Feb;12(1):57-64. PMID 7766287</ref>
'''Mosapramine''' ('''Cremin''') is an [[atypical antipsychotic]] used in [[Japan]] for the treatment of [[schizophrenia]].<ref>{{cite journal | vauthors = Takahashi N, Terao T, Oga T, Okada M | title = Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia | journal = Neuropsychobiology | volume = 39 | issue = 2 | pages = 81–5 | pmid = 10072664 | doi = 10.1159/000026565 | year = 1999 | s2cid = 6554048 }}</ref><ref name=":0">{{cite book | vauthors = Miyamoto S | chapter = Mosapramine | date = 2010 | chapter-url = https://doi.org/10.1007/978-3-540-68706-1_1839 | title = Encyclopedia of Psychopharmacology | pages = 76 | veditors = Stolerman IP | place = Berlin, Heidelberg | publisher = Springer | language = en | doi = 10.1007/978-3-540-68706-1_1839 | isbn = 978-3-540-68706-1 | access-date = 21 March 2022}}</ref> It is a potent [[dopamine antagonist]] with high affinity to the [[Dopamine receptor D2|D<sub>2</sub>]], [[Dopamine receptor D3|D<sub>3</sub>]], and [[Dopamine receptor D4|D<sub>4</sub>]] [[Receptor (biochemistry)|receptors]],<ref>{{cite journal | vauthors = Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T | title = [The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors] | journal = Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 107 | issue = 5 | pages = 247–53 | date = May 1996 | pmid = 8690306 | doi = 10.1254/fpj.107.247 | doi-access = free }}</ref> and with moderate affinity for the [[5-HT2 receptor|5-HT<sub>2</sub> receptors]].<ref>{{cite journal | vauthors = Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K | title = Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy | journal = Neuropsychopharmacology | volume = 12 | issue = 1 | pages = 57–64 | date = February 1995 | pmid = 7766287 | doi = 10.1016/0893-133X(94)00064-7 }}</ref>

== See also ==
* [[Carpipramine]]
* [[Clocapramine]]
* [[Fluspirilene]] (typical antipsychotic)
* [[Imidazopyridine]]


== References ==
== References ==
{{Reflist|2}}
{{Reflist}}



{{Antipsychotics}}
{{Antipsychotics}}
{{Navboxes
{{Adrenergics}}
| title = [[Pharmacodynamics]]
{{Cholinergics}}
| titlestyle = background:#ccccff
{{Dopaminergics}}
| list1 =
{{Histaminergics}}
{{Acetylcholine receptor modulators}}
{{Serotonergics}}
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}
{{Tricyclics}}


{{pharmacology-stub}}


[[Category:Atypical antipsychotics]]
[[Category:Atypical antipsychotics]]
⚫
[[Category:lactams]]
⚫
[[Category:Organochlorides]]
[[Category:Dibenzazepines]]
[[Category:Dibenzazepines]]
⚫
[[Category:Lactams]]
⚫
[[Category:Chloroarenes]]
[[Category:Piperidines]]
[[Category:Pyrrolidones]]
[[Category:Spiro compounds]]


{{nervous-system-drug-stub}}
[[ja:モサプラミン]]

Latest revision as of 02:00, 22 October 2023

Mosapramine
Clinical data
Trade namesCremin (クレミン, JP)
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral (tablets, oral solution)
ATC code
Legal status
Legal status
  • Rx-only (JP)
Identifiers
  • 1'-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]spiro[1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-3,4'-piperidine]-2-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H35ClN4O
Molar mass479.07 g·mol−1
3D model (JSmol)
  • C1CCN2C(C1)NC(=O)C23CCN(CC3)CCCN4C5=CC=CC=C5CCC6=C4C=C(C=C6)Cl
  • InChI=1S/C28H35ClN4O/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34)
  • Key:PXUIZULXJVRBPC-UHFFFAOYSA-N
  (verify)

Mosapramine (Cremin) is an atypical antipsychotic used in Japan for the treatment of schizophrenia.[1][2] It is a potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors,[3] and with moderate affinity for the 5-HT2 receptors.[4]

See also

[edit]

References

[edit]
  1. ^ Takahashi N, Terao T, Oga T, Okada M (1999). "Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia". Neuropsychobiology. 39 (2): 81–5. doi:10.1159/000026565. PMID 10072664. S2CID 6554048.
  2. ^ Miyamoto S (2010). "Mosapramine". In Stolerman IP (ed.). Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 76. doi:10.1007/978-3-540-68706-1_1839. ISBN 978-3-540-68706-1. Retrieved 21 March 2022.
  3. ^ Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T (May 1996). "[The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 107 (5): 247–53. doi:10.1254/fpj.107.247. PMID 8690306.
  4. ^ Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K (February 1995). "Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy". Neuropsychopharmacology. 12 (1): 57–64. doi:10.1016/0893-133X(94)00064-7. PMID 7766287.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Mosapramine&oldid=1181281695"